Peplin Limited (ASX: PEP) announced today the completion late last week of its US based phase I clinical trial for its skin cancer treatment PEP005 Topical. The study was conducted under the investigational new drug (IND) application filed with the US Food and Drug Administration (FDA) in June 2004.
